Cybin Changed Legal Name to Helus Pharma
The clinical-stage developer has rebranded as it shifts toward a commercial-ready pharmaceutical model.
Updated on Oct. 1, 2026 in Healthcare
Cybin Inc. officially changed its legal name to Helus Pharma Inc. effective October 1, 2026. The transition follows shareholder approval and marks the company's move toward a commercial-ready operational focus.
Why it matters
The rebrand signals a strategic pivot from discovery-only activities to becoming a commercial-ready pharmaceutical firm. Operators should track these shifts as indicators of changing capital intensity and regulatory compliance requirements in the sector.
The company issued a new CUSIP number of 423492107 and an ISIN of CA4234921076 for its common shares following the legal name change. Its ticker symbols on Nasdaq and Cboe Canada remain unchanged as HELP.
The players
Helus Pharma Inc.
A pharmaceutical company formerly known as Cybin Inc. that is transitioning from a clinical-stage developer to a commercial-ready enterprise.
The details
Helus Pharma adopted its new identity to better reflect its transformation from a clinical-stage entity into a commercial-ready organization. To facilitate this change, shareholders voted in favor of the transition at the company's annual and special meeting. The business will continue to focus on engineering proprietary drug discovery platforms and innovative delivery systems under the new corporate title.
Timeline
January 5, 2026: The company adopted the business name Helus Pharma.
September 22, 2026: Shareholders approved the formal name change.
October 1, 2026: The legal name change became effective.
Market Landscape
This transition aligns with the 2026 corporate restructuring trend among clinical-stage biotech firms. It follows a established pattern of firms rebranding as they pivot toward commercial-ready operations to improve market positioning.
Investors and partners should update internal records to reflect the new legal entity name, Helus Pharma Inc., for all future filings. Ensure all systems recognize the new CUSIP and ISIN identifiers for common shares to avoid settlement delays.
The takeaway
The name change represents a fundamental shift in business model from drug discovery to commercial readiness. Operators should watch for upcoming technical updates to the company's drug delivery systems and ensure their administrative systems reflect the new CUSIP number 423492107.
Further reading
For broader insights on industry shifts, visit the Healthcare section.
